首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学细胞疗法基因疗法

北美细胞和基因治疗製造服务市场预测至 2030 年 - 区域分析 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）和最终用户

市场调查报告书

商品编码

1452617

北美细胞和基因治疗製造服务市场预测至 2030 年 - 区域分析 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）和最终用户

North America Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 110 Pages | 订单完成后即时交付

价格

简介目录图表

北美细胞和基因治疗製造服务市场预计将从2022年的41.5327亿美元成长到2030年的147.1172亿美元。预计2022年至2030年CAGR为17.1%。

外包细胞和基因治疗製造的日益普及推动北美细胞和基因治疗製造服务市场

细胞和基因疗法的製造是一个复杂的过程，这使得正确执行和监督操作至关重要。细胞和基因治疗製造商了解生物和製程工程的合格人员数量有限。此外，对于经验丰富的团队来说，使用手动和开放製造方法来管理首次临床试验的尝试，然后建立更适合商业的流程可能会很棘手。因此，这些企业选择与合约开发和製造组织（CDMO）合作来加速其临床研究和商业化进程。 CDMO 以合约形式向细胞和基因治疗公司提供产品开发、製造、临床试验支援和商业化服务。与 CDMO 合作可以帮助细胞和基因疗法製造商实现可扩展性、加快上市速度、无需管理成本即可获得技术专业知识以及成本效率。 2022年4月，ThermoGenesis在美国加州建立了CDMO设施，利用其在T细胞受体（TCR）、嵌合抗原受体-T细胞（CAR-T细胞）、肿瘤等领域的专业知识，为细胞和基因治疗製造商提供CDMO服务。- 浸润白血球（TIL）、iPSC、自然杀手细胞（NK）和间质干细胞（MSC）製造。事实证明，将细胞和基因治疗製造外包给 CDMO 对于製造商来说具有成本效益。因此，越来越倾向于将不断增长的细胞和基因治疗製造外包给 CDMO，这推动了北美细胞和基因治疗製造服务市场的成长。

北美细胞与基因治疗製造服务市场概述

细胞和基因疗法 (CGT) 治疗患有严重和罕见疾病且治疗需求未满足的患者。製造 CGT 是一个高度复杂的过程，基础设施和专业知识的不足是一个主要限制。与中间体和最终产品相关的物流挑战也限制了公司的 CGT 製造能力。 CGT的製造过程包括透过「单采术」提取自体细胞，将其送往专门实验室，然后送回诊所给患者施用，所有这些都必须在严格的品质控制下进行。美国食品药物管理局 (USFDA) 仅批准了 7 种 CGT 药物，新产品管线达到约 1,200 种实验疗法。其中一半处于2 期临床试验中，根据2022 年《化学与工程新闻》报告的估计，细胞疗法的年销售额增长预计为15%，基因疗法的年销售额增长约为30%。2022 年3 月31 日， CELL Technologies Inc. 宣布已提交其疼痛和关节炎干细胞计画的临床资料，以供加拿大卫生部批准，以帮助患者在加拿大各地获得基于证据和监管批准的干细胞程序。因此，预计上述因素将在预测期内促进细胞和基因治疗製造服务市场的成长。因此，上述因素推动了北美细胞和基因治疗製造服务市场的成长。

北美细胞和基因治疗製造服务市场收入及 2030 年预测（百万美元）

北美细胞和基因治疗製造服务市场细分

北美细胞和基因治疗製造服务市场分为类型、适应症、应用、最终用户和国家。

根据类型，北美细胞和基因治疗製造服务市场分为细胞治疗和基因治疗。 2022年，细胞治疗领域在北美细胞和基因治疗製造服务市场中占据更大份额。细胞治疗部分进一步分为自体细胞治疗和同种异体细胞治疗。基因治疗部分进一步细分为病毒载体和非病毒载体。

根据迹象，北美细胞和基因治疗製造服务市场分为癌症、骨科等。 2022年，癌症领域在北美细胞和基因治疗製造服务市场中占据最大份额。

根据应用，北美细胞和基因治疗製造服务市场分为临床製造和商业製造。 2022年，商业製造领域在北美细胞和基因治疗製造服务市场中占据最大份额。

根据最终用户，北美细胞和基因治疗製造服务市场分为製药和生物技术公司和合约研究组织（CRO）。 2022年，製药和生物技术公司部门在北美细胞和基因治疗製造服务市场中占据更大份额。

根据国家/地区，北美细胞和基因治疗製造服务市场分为美国、加拿大和墨西哥。 2022年，美国在北美细胞和基因治疗製造服务市场中占据最大份额。

Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、National Resilience Inc、Nikon Corp、Oxford BioMedica Plc、Takara Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是一些领先的公司在 Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是一些领先的公司在 Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是一些领先的公司在 Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是一些领先的公司在 Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是一些领先的公司在 Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd北美细胞和基因治疗製造服务市场运营的公司。

Cell and gene therapy manufacturing is a complex process, which makes the proper execution and overseeing of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual, and open manufacturing method and then building a more commercially suitable process can be tricky. Therefore, these enterprises choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs provide product development, manufacturing, clinical trial support, and commercialization services to cell and gene therapy companies on a contract basis. Partnering with a CDMO enables scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies for cell and gene therapy manufacturers. In April 2022, ThermoGenesis established a CDMO facility in California, US to provide CDMO services to cell and gene therapy manufacturers, using its expertise in T-cell receptor (TCR), chimeric antigen receptor-T cell (CAR-T cell), tumor-infiltrating leukocyte (TIL), iPSC, natural killer cell (NK), and mesenchymal stem cell (MSC) manufacturing. Outsourcing cell and gene therapy manufacturing to CDMOs proves cost-effective for manufacturers. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the North America cell and gene therapy manufacturing services market growth.

North America Cell and Gene Therapy Manufacturing Services Market Overview

Cell and gene therapies (CGTs) treat patients suffering from serious and rare diseases with unaddressed therapeutic needs. Manufacturing CGTs is a highly complex process, with the insufficiency of infrastructure and expertise being a major limiting factor. Logistical challenges associated with intermediates and the final product also limit the CGT manufacturing capacity of companies. The CGT manufacturing process involves the extraction of autologous cells through "apheresis," dispatching them to specialized labs, and sending them back to clinics for administration into patients, all of which must be performed with strict quality control. The US Food and Drug Administration (USFDA) has approved only 7 CGT drugs, with the pipeline of new products reaching ~1,200 experimental therapies. Half of these are in Phase 2 clinical trials, with estimates of annual sales growth accounting for 15% for cell therapies and ~30% for gene therapies, as per the estimates of the Chemical & Engineering News report 2022. On March 31, 2022, CELL Technologies Inc. announced the submission of the clinical data of its stem cell program in pain and arthritis for approval by Health Canada to help patients access evidence-based and regulatory-approved stem cell procedures across Canada. Thus, the abovementioned factors are expected to promote the cell and gene therapy manufacturing services market growth during the forecast period. Thus, the abovementioned factors are responsible for the growth of the North America cell and gene therapy manufacturing services market.

North America Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

North America Cell and Gene Therapy Manufacturing Services Market Segmentation

The North America cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the North America cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the North America cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the North America cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the North America cell and gene therapy manufacturing services market.

Based on application, the North America cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the North America cell and gene therapy manufacturing services market.

Based on end user, the North America cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the North America cell and gene therapy manufacturing services market.

Based on country, the North America cell and gene therapy manufacturing services market is segmented into the US, Canada, Mexico. In 2022, the US registered the largest share in the North America cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, National Resilience Inc, Nikon Corp, Oxford BioMedica Plc, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the North America cell and gene therapy manufacturing services market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Increase in Number of Approval of Cell and Gene Therapies
- 4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
4.2 Market Restraints
- 4.2.1 High Cost of Cell and Gene Therapy Manufacturing
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Companies
4.4 Future Trends
- 4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
4.5 Impact Analysis:

5. Cell and Gene Therapy Manufacturing Services Market - North America Market Analysis

5.1 North America Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030

6. North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Cell Therapy
- 6.3.1 Overview
- 6.3.2 Cell Therapy: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Autologous
    - 6.3.2.1.1 Overview
    - 6.3.2.1.2 Autologous: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.2 Allogenic
    - 6.3.2.2.1 Overview
    - 6.3.2.2.2 Allogenic: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Gene Therapy
- 6.4.1 Overview
- 6.4.2 Gene Therapy: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.1 Viral Vector
    - 6.4.2.1.1 Overview
    - 6.4.2.1.2 Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.2 Non-Viral Vector
    - 6.4.2.2.1 Overview
    - 6.4.2.2.2 Non-Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

7.1 Overview
7.2 North America Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Orthopedics
- 7.4.1 Overview
- 7.4.2 Orthopedics: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
8.4 Clinical Manufacturing
- 8.4.1 Overview
- 8.4.2 Clinical Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Commercial Manufacturing
- 8.5.1 Overview
- 8.5.2 Commercial Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
9.4 Pharmaceutical and Biotechnology Companies
- 9.4.1 Overview
- 9.4.2 Pharmaceutical & Biotechnology Companies: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Contract Research Organizations (CROs)
- 9.5.1 Overview
- 9.5.2 Contract Research Organizations (CROs): North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview
- 10.1.1 North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  - 10.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.1.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.1.3 US: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.1.4 US: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.2 Canada: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.2.1.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.2.1.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.2.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.2.3 Canada: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.2.4 Canada: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.3 Mexico: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 10.1.1.3.1.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 10.1.1.3.1.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 10.1.1.3.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.1.3.3 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.3.4 Mexico: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

11. North America Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Thermo Fisher Scientific Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck KGaA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Lonza Group AG
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 WuXi AppTec Co Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Takara Bio Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Nikon Corp
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 FUJIFILM Holdings Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 National Resilience Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Oxford BioMedica Plc
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

简介目录图表

List Of Tables

Table 1. North America Cell and Gene Therapy Manufacturing Services Market Segmentation
Table 2. US: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. US: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. US: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. US: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. US: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. US: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. Canada: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. Canada: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 12. Canada: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. Canada: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. Mexico: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Recent Organic Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
Table 21. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Manufacturing Services Market

List Of Figures

Figure 1. North America Cell and Gene Therapy Manufacturing Services Market Segmentation, By Country
Figure 2. North America Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Cell Therapy: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Autologous: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Allogenic: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Gene Therapy: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Non-Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. North America Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 13. Cancer: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Orthopedics: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 17. Clinical Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Commercial Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 20. Pharmaceutical & Biotechnology Companies: North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Contract Research Organizations (CROs): North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. North America: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
Figure 23. North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
Figure 24. US: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Canada: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. Mexico: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Growth Strategies in Cell and Gene Therapy Manufacturing Services Market

02-2729-4219

+886-2-2729-4219

License/价格

北美细胞和基因治疗製造服务市场预测至 2030 年 - 区域分析 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）和最终用户

North America Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

目录

第 1 章：简介

第 2 章：执行摘要

第 3 章：研究方法

第 4 章：北美细胞和基因治疗製造服务市场 - 主要产业动态

第 5 章：细胞与基因治疗製造服务市场 - 北美市场分析

第 6 章：北美细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按类型

第 7 章：2030 年北美细胞和基因治疗製造服务市场分析和预测 - 按指标

第 8 章：北美细胞和基因治疗製造服务市场 - 收入和 2030 年预测 -按应用

第 9 章：北美细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按最终用户

第 10 章：北美细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 国家分析

第 11 章：北美细胞与基因疗法製造服务市场 - 产业格局

第 12 章：公司简介

Table Of Contents